Thoughts on COVID-19 and autoimmune diseases
Identifieur interne : 000075 ( 2020/Analysis ); précédent : 000074; suivant : 000076Thoughts on COVID-19 and autoimmune diseases
Auteurs : Anca D. Askanase [États-Unis] ; Leila Khalili [États-Unis] ; Jill P. Buyon [États-Unis]Source :
- Lupus Science & Medicine [ 2053-8790 ] ; 2020.
Descripteurs français
- KwdFr :
- Anticorps monoclonaux humanisés (usage thérapeutique), Azétidines (usage thérapeutique), Chloroquine (usage thérapeutique), Humains, Hydroxychloroquine (usage thérapeutique), Immunomodulation, Immunosuppression thérapeutique, Infections à coronavirus (), Infections à coronavirus (traitement médicamenteux), Maladies auto-immunes (), Pandémies, Pneumopathie virale (), Pneumopathie virale (traitement médicamenteux), Rhumatologie, Sulfonamides (usage thérapeutique).
- MESH :
- traitement médicamenteux : Infections à coronavirus, Pneumopathie virale.
- usage thérapeutique : Anticorps monoclonaux humanisés, Azétidines, Chloroquine, Hydroxychloroquine, Sulfonamides.
- Humains, Immunomodulation, Immunosuppression thérapeutique, Infections à coronavirus, Maladies auto-immunes, Pandémies, Pneumopathie virale, Rhumatologie.
English descriptors
- KwdEn :
- Antibodies, Monoclonal, Humanized (therapeutic use), Autoimmune Diseases (complications), Autoimmune Diseases (therapy), Azetidines (therapeutic use), Betacoronavirus, Chloroquine (therapeutic use), Coronavirus Infections (complications), Coronavirus Infections (drug therapy), Cytokine Release Syndrome, Humans, Hydroxychloroquine (therapeutic use), Immunomodulation, Immunosuppression, Pandemics, Pneumonia, Viral (complications), Pneumonia, Viral (drug therapy), Rheumatology, Sulfonamides (therapeutic use).
- MESH :
- chemical , therapeutic use : Antibodies, Monoclonal, Humanized, Azetidines, Chloroquine, Hydroxychloroquine, Sulfonamides.
- complications : Autoimmune Diseases, Coronavirus Infections, Pneumonia, Viral.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- therapy : Autoimmune Diseases.
- Betacoronavirus, Cytokine Release Syndrome, Humans, Immunomodulation, Immunosuppression, Pandemics, Rheumatology.
Abstract
Over the 2 months since coronavirus first appeared in China, cases have emerged on every continent, and it is clear that patients with autoimmune diseases might also be affected. Coronavirus disease 2019 (COVID-19) is a highly contagious viral illness with a mortality rate approaching 2%. Here we discuss the challenges that patients with autoimmune diseases might face and the information on using immunomodulatory therapies like chloroquine, tocilizumab and baricitinib to quench the cytokine storm in patients with very severe COVID-19 pneumonia.
Url:
DOI: 10.1136/lupus-2020-000396
PubMed: 32341791
PubMed Central: 7174058
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 000701
- to stream Pmc, to step Curation: 000701
- to stream Pmc, to step Checkpoint: 000032
- to stream PubMed, to step Corpus: 000015
- to stream PubMed, to step Curation: 000015
- to stream PubMed, to step Checkpoint: 000054
- to stream Ncbi, to step Merge: 002C76
- to stream Ncbi, to step Curation: 002C76
- to stream Ncbi, to step Checkpoint: 002C76
- to stream Main, to step Merge: 000075
- to stream Main, to step Curation: 000075
- to stream Main, to step Exploration: 000075
- to stream 2020, to step Extraction: 000075
Links to Exploration step
PMC:7174058Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Thoughts on COVID-19 and autoimmune diseases</title><author><name sortKey="Askanase, Anca D" sort="Askanase, Anca D" uniqKey="Askanase A" first="Anca D" last="Askanase">Anca D. Askanase</name><affiliation wicri:level="1"><nlm:aff id="aff1"><institution content-type="department">Department of Rheumatology</institution>,<institution>Columbia University Medical Center</institution>,<addr-line content-type="city">New York</addr-line>,<addr-line content-type="state">New York</addr-line>,<country>USA</country></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Khalili, Leila" sort="Khalili, Leila" uniqKey="Khalili L" first="Leila" last="Khalili">Leila Khalili</name><affiliation wicri:level="1"><nlm:aff id="aff1"><institution content-type="department">Department of Rheumatology</institution>,<institution>Columbia University Medical Center</institution>,<addr-line content-type="city">New York</addr-line>,<addr-line content-type="state">New York</addr-line>,<country>USA</country></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Buyon, Jill P" sort="Buyon, Jill P" uniqKey="Buyon J" first="Jill P" last="Buyon">Jill P. Buyon</name><affiliation wicri:level="1"><nlm:aff id="aff2"><institution content-type="department">Department of Rheumatology</institution>,<institution>NYU Langone Health</institution>,<addr-line content-type="city">New York</addr-line>,<addr-line content-type="state">New York</addr-line>,<country>USA</country></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">32341791</idno><idno type="pmc">7174058</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7174058</idno><idno type="RBID">PMC:7174058</idno><idno type="doi">10.1136/lupus-2020-000396</idno><date when="2020">2020</date><idno type="wicri:Area/Pmc/Corpus">000701</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000701</idno><idno type="wicri:Area/Pmc/Curation">000701</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000701</idno><idno type="wicri:Area/Pmc/Checkpoint">000032</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000032</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:32341791</idno><idno type="wicri:Area/PubMed/Corpus">000015</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000015</idno><idno type="wicri:Area/PubMed/Curation">000015</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000015</idno><idno type="wicri:Area/PubMed/Checkpoint">000054</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000054</idno><idno type="wicri:Area/Ncbi/Merge">002C76</idno><idno type="wicri:Area/Ncbi/Curation">002C76</idno><idno type="wicri:Area/Ncbi/Checkpoint">002C76</idno><idno type="wicri:Area/Main/Merge">000075</idno><idno type="wicri:Area/Main/Curation">000075</idno><idno type="wicri:Area/Main/Exploration">000075</idno><idno type="wicri:Area/2020/Extraction">000075</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Thoughts on COVID-19 and autoimmune diseases</title><author><name sortKey="Askanase, Anca D" sort="Askanase, Anca D" uniqKey="Askanase A" first="Anca D" last="Askanase">Anca D. Askanase</name><affiliation wicri:level="1"><nlm:aff id="aff1"><institution content-type="department">Department of Rheumatology</institution>,<institution>Columbia University Medical Center</institution>,<addr-line content-type="city">New York</addr-line>,<addr-line content-type="state">New York</addr-line>,<country>USA</country></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Khalili, Leila" sort="Khalili, Leila" uniqKey="Khalili L" first="Leila" last="Khalili">Leila Khalili</name><affiliation wicri:level="1"><nlm:aff id="aff1"><institution content-type="department">Department of Rheumatology</institution>,<institution>Columbia University Medical Center</institution>,<addr-line content-type="city">New York</addr-line>,<addr-line content-type="state">New York</addr-line>,<country>USA</country></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Buyon, Jill P" sort="Buyon, Jill P" uniqKey="Buyon J" first="Jill P" last="Buyon">Jill P. Buyon</name><affiliation wicri:level="1"><nlm:aff id="aff2"><institution content-type="department">Department of Rheumatology</institution>,<institution>NYU Langone Health</institution>,<addr-line content-type="city">New York</addr-line>,<addr-line content-type="state">New York</addr-line>,<country>USA</country></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author></analytic><series><title level="j">Lupus Science & Medicine</title><idno type="eISSN">2053-8790</idno><imprint><date when="2020">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibodies, Monoclonal, Humanized (therapeutic use)</term><term>Autoimmune Diseases (complications)</term><term>Autoimmune Diseases (therapy)</term><term>Azetidines (therapeutic use)</term><term>Betacoronavirus</term><term>Chloroquine (therapeutic use)</term><term>Coronavirus Infections (complications)</term><term>Coronavirus Infections (drug therapy)</term><term>Cytokine Release Syndrome</term><term>Humans</term><term>Hydroxychloroquine (therapeutic use)</term><term>Immunomodulation</term><term>Immunosuppression</term><term>Pandemics</term><term>Pneumonia, Viral (complications)</term><term>Pneumonia, Viral (drug therapy)</term><term>Rheumatology</term><term>Sulfonamides (therapeutic use)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Anticorps monoclonaux humanisés (usage thérapeutique)</term><term>Azétidines (usage thérapeutique)</term><term>Chloroquine (usage thérapeutique)</term><term>Humains</term><term>Hydroxychloroquine (usage thérapeutique)</term><term>Immunomodulation</term><term>Immunosuppression thérapeutique</term><term>Infections à coronavirus ()</term><term>Infections à coronavirus (traitement médicamenteux)</term><term>Maladies auto-immunes ()</term><term>Pandémies</term><term>Pneumopathie virale ()</term><term>Pneumopathie virale (traitement médicamenteux)</term><term>Rhumatologie</term><term>Sulfonamides (usage thérapeutique)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Monoclonal, Humanized</term><term>Azetidines</term><term>Chloroquine</term><term>Hydroxychloroquine</term><term>Sulfonamides</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Autoimmune Diseases</term><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Autoimmune Diseases</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anticorps monoclonaux humanisés</term><term>Azétidines</term><term>Chloroquine</term><term>Hydroxychloroquine</term><term>Sulfonamides</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Betacoronavirus</term><term>Cytokine Release Syndrome</term><term>Humans</term><term>Immunomodulation</term><term>Immunosuppression</term><term>Pandemics</term><term>Rheumatology</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Humains</term><term>Immunomodulation</term><term>Immunosuppression thérapeutique</term><term>Infections à coronavirus</term><term>Maladies auto-immunes</term><term>Pandémies</term><term>Pneumopathie virale</term><term>Rhumatologie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>Over the 2 months since coronavirus first appeared in China, cases have emerged on every continent, and it is clear that patients with autoimmune diseases might also be affected. Coronavirus disease 2019 (COVID-19) is a highly contagious viral illness with a mortality rate approaching 2%. Here we discuss the challenges that patients with autoimmune diseases might face and the information on using immunomodulatory therapies like chloroquine, tocilizumab and baricitinib to quench the cytokine storm in patients with very severe COVID-19 pneumonia.</p></div></front><back><div1 type="bibliography"><listBibl><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Zhang, W" uniqKey="Zhang W">W Zhang</name></author><author><name sortKey="Du, R H" uniqKey="Du R">R-H Du</name></author><author><name sortKey="Li, B" uniqKey="Li B">B Li</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bai, Y" uniqKey="Bai Y">Y Bai</name></author><author><name sortKey="Yao, L" uniqKey="Yao L">L Yao</name></author><author><name sortKey="Wei, T" uniqKey="Wei T">T Wei</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Niewold, Tb" uniqKey="Niewold T">TB Niewold</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Yee, Am" uniqKey="Yee A">AM Yee</name></author><author><name sortKey="Buyon, Jp" uniqKey="Buyon J">JP Buyon</name></author><author><name sortKey="Yip, Yk" uniqKey="Yip Y">YK Yip</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Preble, O" uniqKey="Preble O">O Preble</name></author><author><name sortKey="Black, R" uniqKey="Black R">R Black</name></author><author><name sortKey="Friedman, R" uniqKey="Friedman R">R Friedman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pene, F" uniqKey="Pene F">F Pene</name></author><author><name sortKey="Merlat, A" uniqKey="Merlat A">A Merlat</name></author><author><name sortKey="Vabret, A" uniqKey="Vabret A">A Vabret</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chen, N" uniqKey="Chen N">N Chen</name></author><author><name sortKey="Zhou, M" uniqKey="Zhou M">M Zhou</name></author><author><name sortKey="Dong, X" uniqKey="Dong X">X Dong</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pan, F" uniqKey="Pan F">F Pan</name></author><author><name sortKey="Ye, T" uniqKey="Ye T">T Ye</name></author><author><name sortKey="Sun, P" uniqKey="Sun P">P Sun</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Xu, Z" uniqKey="Xu Z">Z Xu</name></author><author><name sortKey="Shi, L" uniqKey="Shi L">L Shi</name></author><author><name sortKey="Wang, Y" uniqKey="Wang Y">Y Wang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wang, M" uniqKey="Wang M">M Wang</name></author><author><name sortKey="Cao, R" uniqKey="Cao R">R Cao</name></author><author><name sortKey="Zhang, L" uniqKey="Zhang L">L Zhang</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Yao, X" uniqKey="Yao X">X Yao</name></author><author><name sortKey="Ye, F" uniqKey="Ye F">F Ye</name></author><author><name sortKey="Zhang, M" uniqKey="Zhang M">M Zhang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Liu, J" uniqKey="Liu J">J Liu</name></author><author><name sortKey="Cao, R" uniqKey="Cao R">R Cao</name></author><author><name sortKey="Xu, M" uniqKey="Xu M">M Xu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gao, J" uniqKey="Gao J">J Gao</name></author><author><name sortKey="Tian, Z" uniqKey="Tian Z">Z Tian</name></author><author><name sortKey="Yang, X" uniqKey="Yang X">X Yang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gautret, P" uniqKey="Gautret P">P Gautret</name></author><author><name sortKey="Lagier, J" uniqKey="Lagier J">J Lagier</name></author><author><name sortKey="Parola, P" uniqKey="Parola P">P Parola</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chen, J" uniqKey="Chen J">J Chen</name></author><author><name sortKey="Liu, D" uniqKey="Liu D">D Liu</name></author><author><name sortKey="Liu, L" uniqKey="Liu L">L Liu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Channappanavar, R" uniqKey="Channappanavar R">R Channappanavar</name></author><author><name sortKey="Perlman, S" uniqKey="Perlman S">S Perlman</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Richardson, P" uniqKey="Richardson P">P Richardson</name></author><author><name sortKey="Griffin, I" uniqKey="Griffin I">I Griffin</name></author><author><name sortKey="Tucker, C" uniqKey="Tucker C">C Tucker</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Stebbing, J" uniqKey="Stebbing J">J Stebbing</name></author><author><name sortKey="Phelan, A" uniqKey="Phelan A">A Phelan</name></author><author><name sortKey="Griffin, I" uniqKey="Griffin I">I Griffin</name></author></analytic></biblStruct></listBibl></div1></back></TEI><affiliations><list><country><li>États-Unis</li></country></list><tree><country name="États-Unis"><noRegion><name sortKey="Askanase, Anca D" sort="Askanase, Anca D" uniqKey="Askanase A" first="Anca D" last="Askanase">Anca D. Askanase</name></noRegion><name sortKey="Buyon, Jill P" sort="Buyon, Jill P" uniqKey="Buyon J" first="Jill P" last="Buyon">Jill P. Buyon</name><name sortKey="Khalili, Leila" sort="Khalili, Leila" uniqKey="Khalili L" first="Leila" last="Khalili">Leila Khalili</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/2020/Analysis
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000075 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/2020/Analysis/biblio.hfd -nk 000075 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= TocilizumabV1
|flux= 2020
|étape= Analysis
|type= RBID
|clé= PMC:7174058
|texte= Thoughts on COVID-19 and autoimmune diseases
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/2020/Analysis/RBID.i -Sk "pubmed:32341791" \
| HfdSelect -Kh $EXPLOR_AREA/Data/2020/Analysis/biblio.hfd \
| NlmPubMed2Wicri -a TocilizumabV1
| This area was generated with Dilib version V0.6.34. |  |